Our Mission

Safety. Supply. Efficacy.

By combining excellence in protein and adjuvant biology, we are focused on creating a new generation of adjuvanted subunit vaccines of global importance for the treatment and prevention of infectious diseases.

Brief History

Curevo Vaccine Origins

2017

Collaboration

Research Collaboration between IDRI and MOGAM Institute for Biomedical Research (part of GC Pharma).

2017
Collaboration
2018

Curevo

Curevo Vaccine was created as the vehicle to develop and launch CRV-101 – Shingles Vaccine. We opened our first office in downtown Seattle with 2 employees - Emma Fritzen and Lisa Shelton.

2018
Curevo
2019

Phase I

Phase I clinical trial started to analyze the safety and immunology data. George Simeon joins the company as a CEO and Julie Brooks as a General Counsel.

2019
Phase I
2020

Phase I Completed

Phase I trial was completed with successful results. Four more team members join our team including Greg Curhan as a CFO, Anna Wrem as a Program Manager, and Shannan Moran as an Office Manager.

2020
Phase I Completed
2021

Immunology

Phase 1 trial immunology completed. Three more members join our team - Renae Koepke, Paul FitzMorris & Aaron Shoemaker. Preparations for Phase II and EMA EA Submission.

2021
Immunology
2021

Series-A

On December 30th, we closed a $60M Series-A financing round led by RA Capital, Adjuvant Capital, Janus Henderson Investors, GC Pharma, and e&.

2021
Series-A
2022

Phase 2b

Phase 2b clinical trial starts. Four new members join Curevo team - Megan Real-Hall, Sein Pyo, Andrea Wang and Svetlana Betz. We move to our new office in Bothell, WA.

2022
Phase 2b

Our History